Dr. Fenghua Wang 王风华
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of gastrointestinal tumors (colorectal, gastric, esophageal, pancreatic, biliary tract, neuroendocrine) and advanced nasopharyngeal cancer.
Dr. Wang holds a PhD in Oncology from Sun Yat-sen University. Since 1994, Dr. Wang has specialized in chemotherapy, targeted therapy, and multidisciplinary care for gastrointestinal cancers and supportive care for advanced cancer. Research interests include gene polymorphisms in nasopharyngeal cancer chemotherapy response and targeted nanotherapies.
Professional roles
- Standing Committee Member and Secretary, Tumor Targeted Therapy Professional Committee, China Anti-Cancer Association
- Member, Clinical Chemotherapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Gastric Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Digestive Tumor Professional Committee, Guangdong Female Physicians Association
Name order: in Chinese the family name comes first (Wang Fenghua). Papers usually list the name as Fenghua Wang or Wang F.
Selected publications
162 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Clinicopathological features and treatment paradigms exploration in advanced ampullary cancer. PubMed 42827754
- Clin Transl Med, 2026 (senior author): deltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types. PubMed 41601354
- Nat Med, 2024 (first author): Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. PubMed 38438735
- Pancreatology, 2024 (first author): Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. PubMed 38195328
- Cancer Commun (Lond), 2024 (first author): The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. PubMed 38160327
- J Inflamm Res, 2022 (first author): PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis. PubMed 36339826
- Clin Cancer Res, 2022 (first author): A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). PubMed 35929990
- Gut, 2022 (first author): Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. PubMed 34489309
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion